, Tracking Stock Market Picks
Enter Symbol:
Rating: MNKD
Underweight $0.05

Mannkind Corporation (NASDAQ: MNKD) downgraded to Underweight with price target $0.05 by Piper Jaffray

Wednesday,  Jan 6, 2016  10:25 AM ET by Dave Ficere

Piper Jaffray downgraded Mannkind Corporation (NASDAQ: MNKD) to Underweight with
price target $0.05. Previously Piper Jaffray rated Neutral Mannkind Corporation (NASDAQ: MNKD) on 11/27/2013, when the stock price was $5.02.

Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung.

At Piper Jaffray, we understand there’s no substitute for relevant and timely research. That's why we provide: * fundamental and technical research * value-added investment ideas * market analysis With the information our research team provides, you’ll make better and more informed decisions for your portfolio.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy